The OnePlus 13 has now been announced for the U.S., and if you've bought one, you'll want to keep it safe with one of the ...

True, one of the drugmaker's leading candidates, CagriSema, recently failed to impress investors in a phase 3 study. Upon closer inspection, though, Novo Nordisk's "disappointing" late-stage ...

Unleash your creativity with these fun DIY projects for making adorable purses, credit card holders, and phone cases. Using ...

Discover fun and creative DIY phone cases designed to relieve stress while adding a cute touch to your phone! These easy-to-follow life hacks combine art, craft, and relaxation, allowing you to create ...

This MagSafe case is from Spigen, known for its line of sleek gear and accessories made for those on the go. The Optik Armor ...

This was due to disappointing late-stage trial results for its experimental weight-loss drug, CagriSema. Novo Nordisk has partnered with Photys Therapeutics to develop a novel therapeutic ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Executive Editor David Carnoy has been a leading member of CNET's Reviews team since 2000. He covers the gamut of gadgets and is a notable reviewer of mobile accessories and portable audio ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital ...